Chimeric Therapeutics Ltd (ASX: CHM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Chimeric Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Chimeric Therapeutics Ltd (ASX: CHM)
Latest News
Healthcare Shares
Guess which ASX micro-cap stock is rocketing 80% on FDA clearance
Healthcare Shares
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
Share Gainers
The Chimeric (ASX:CHM) share price jumps 6% on patent success
Healthcare Shares
The Chimeric (ASX:CHM) share price drops despite cancer trial news
Share Market News
Chimeric (ASX:CHM) share price finishes flat on quarterly update
Share Market News
Chimeric (ASX:CHM) share price edges lower despite positive update
Share Market News
Chimeric (ASX:CHM) share price falls despite positive update
Share Market News
Chimeric Therapeutics (ASX:CHM) share price jumps 88% following its IPO
CHM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
CHM Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Dec 2024 | $0.01 | $0.00 | 0.00% | 4,515,921 | $0.01 | $0.01 | $0.01 |
20 Dec 2024 | $0.01 | $0.00 | 0.00% | 1,481,106 | $0.01 | $0.01 | $0.01 |
19 Dec 2024 | $0.01 | $0.00 | 0.00% | 4,139,804 | $0.01 | $0.01 | $0.01 |
18 Dec 2024 | $0.01 | $0.00 | 0.00% | 2,499,362 | $0.01 | $0.01 | $0.01 |
17 Dec 2024 | $0.01 | $0.00 | 0.00% | 11,330,163 | $0.01 | $0.01 | $0.01 |
16 Dec 2024 | $0.01 | $0.00 | 0.00% | 7,908,312 | $0.01 | $0.01 | $0.01 |
13 Dec 2024 | $0.01 | $0.00 | 0.00% | 2,013,475 | $0.01 | $0.01 | $0.01 |
12 Dec 2024 | $0.01 | $0.00 | 0.00% | 2,392,854 | $0.01 | $0.01 | $0.01 |
11 Dec 2024 | $0.01 | $0.00 | 0.00% | 1,502,867 | $0.01 | $0.01 | $0.01 |
10 Dec 2024 | $0.01 | $0.00 | 0.00% | 24,086,007 | $0.01 | $0.01 | $0.01 |
09 Dec 2024 | $0.01 | $0.00 | 0.00% | 3,420,168 | $0.01 | $0.01 | $0.01 |
06 Dec 2024 | $0.01 | $0.00 | 0.00% | 17,523,136 | $0.01 | $0.01 | $0.01 |
05 Dec 2024 | $0.01 | $0.00 | 0.00% | 9,884,779 | $0.01 | $0.01 | $0.01 |
04 Dec 2024 | $0.01 | $0.00 | 0.00% | 3,241,167 | $0.01 | $0.01 | $0.01 |
03 Dec 2024 | $0.01 | $0.00 | 0.00% | 5,966,094 | $0.01 | $0.01 | $0.01 |
02 Dec 2024 | $0.01 | $0.00 | 0.00% | 932,500 | $0.01 | $0.01 | $0.01 |
29 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,033,465 | $0.01 | $0.01 | $0.01 |
28 Nov 2024 | $0.01 | $0.00 | 0.00% | 5,689,069 | $0.01 | $0.01 | $0.01 |
27 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,101,970 | $0.01 | $0.01 | $0.01 |
26 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,451,000 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
13 Dec 2024 | Paul Hopper | Issued | 11,580,882 | $69,485 |
Issue of options.
|
13 Dec 2024 | Paul Hopper | Issued | 100,000,000 | $600,000 |
Placement.
|
09 Dec 2024 | Paul Hopper | Issued | 20,000,000 | $160,000 |
Placement.
|
09 Dec 2024 | Paul Hopper | Issued | 80,000,000 | $640,000 |
Placement.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Phillip Hains | Chief Financial OfficerJoint Company SecretaryNon Executive Director | Jul 2023 |
Mr Hains has over 30 years of extensive experience in roles with a portfolio of ASX and NASDAQ listed companies.
|
Mr Paul Alex Hopper | FounderExecutive ChairmanExecutive Director | Feb 2020 |
Mr Hopper is founder and Executive Chairman since February 2021. Mr Hopper is also currently Executive Chairman at Imugene Limited (ASX: IMU), which he founded in October 2012 and Radiopharm Theranostics Limited (ASX: RAD), which he founded in 2021. In addition, Mr. Hopper was also previously Chairman at Viralytics Limited (ASX:VLA) until it was acquired by Merck in 2018. He was previously Executive Chairman of Arovella Therapeutics (ASX: PTX) between May 2019 and June 2022, as well as a director of Prescient Therapeutics Limited (ASX: PTX) from May 2014 to January 2020. Mr Hopper brings 20 years of experience in the management and funding of biotechnology and healthcare companies in Australia and the United States.
|
Dr Lesley Russell | Non-Executive Director | Aug 2020 |
Dr Russell has over 25 years of experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both FDA and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of Risk Committee.
|
Mr Eric Sullivan | Non-Executive Director | Aug 2023 |
Mr Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. He is Chair of Risk Committee.
|
Mr Nathan Jong | Joint Company Secretary |
-
|
|
Nathan Jong | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 78,532,782 | 8.68% |
Lind Global Fund Ii Lp | 21,676,135 | 2.40% |
Mr Evangelos Kalafatas | 19,068,488 | 2.11% |
Zerrin Investments Pty Ltd | 17,600,001 | 1.94% |
Solium Nominees (Australia) Pty Ltd | 17,069,307 | 1.89% |
BNP Paribas Nominees Pty Ltd | 16,936,847 | 1.87% |
Kilinwata Investments Pty Ltd | 15,984,654 | 1.77% |
Kamala Holdings Pty Ltd | 14,500,000 | 1.60% |
Christine Brown | 12,163,170 | 1.34% |
Valentino Trading Pty Ltd | 12,000,000 | 1.33% |
Palm Beach Nominees Pty Limited | 11,724,758 | 1.30% |
Michael E Barish | 11,522,634 | 1.27% |
Mr Lubomir Haralambev & Mrs Emilia Sotirova-Haralambeva | 10,000,000 | 1.10% |
Australian Direct Investments Pty Limited | 9,969,684 | 1.10% |
Mr Mark Desmond Simpson | 9,349,593 | 1.03% |
HSBC Custody Nominees (Australia) Limited | 9,174,139 | 1.01% |
Syrax Investments Pty Ltd | 9,000,000 | 0.99% |
Mbantua Holdings Pty Ltd | 8,500,000 | 0.94% |
Scarlett Augusta Hopper | 8,295,120 | 0.92% |
Mr Tim Bensley & Ms Jenny Jiaer Zhang | 7,509,562 | 0.83% |